Protagonist Therapeutics, Inc. (PTGX) Stock Grade

About Protagonist Therapeutics, Inc.'s fundamentals

Protagonist Therapeutics is a biotechnology company with a market capitalization of $5.6 billion that is currently unprofitable, reporting a net loss in its latest annual statement and a net margin of -282.8%. Revenue declined sharply year-over-year by 89.4%, indicating a significant contraction in sales. Despite these accounting losses, the company maintains positive free cash flow, suggesting it is generating cash from operations even as it burns through capital in development or other strategic areas. The company does not pay a dividend and has no traditional earnings-based valuation metrics available.